Article Text

PDF

IS-065 Hemangiomas: Oral Propanolol And Beyond
  1. E Baselga
  1. Dermatology, Hospital de La Santa Creu i Sant Pau, Barcelona, Spain

Abstract

Hemangiomas are benign vascular tumours that slowly involute over many years. Therefore most hemangiomas do not require treatment. However approximately 38% of hemangiomas can be complicated depending on their subtype, location, and size. Straightforward indications for treatment include ulceration, interference with vital functions, or large size. Risk of disfigurement can be a more controversial indication. Since 2008, propranolol has dramatically changed the treatment of hemangiomas and is considered first-line treatment in complicated infantile hemangiomas (IH). In these years of clinical use, together with the results of a multicenter randomised clinical trial we have gained insight on efficacy and safety. Propanolol is highly effective and is usually given in a dose range of 2–3 mg/kg in BID for 6 to 9 months. Rebound after stopping treatment is possible in 15–19% of patients. Type of monitoring before initiating therapy has been modified over these past years and after the results of the clinical trial it is recommended a good physical exam with cardiac auscultation and control of blood pressure and cardiac frequency. Because its efficacy and safety risk of disfigurement has become a common indication to treat. There are several factors of the hemangioma itself and location that may help to predict or anticipate the residuum after involution of the hemangioma is completed.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.